NCI Conducts Study to Acquire Biospecimens for NCT02682667, Supporting Clinical Trials for Immunotherapy
The Need for Customized Biobanking in Immunotherapy
The Center for Immuno-Oncology (CIO) at the National Cancer Institute (NCI) is conducting an observational study (NCT02682667) to collect biospecimens from 500 patients to elucidate the responsiveness to immunotherapy. Initiated in April 2016, this study aims to systematically acquire high-quality biospecimens, including tumor tissue, blood, and bone marrow aspirates. Unlike conventional biobanks, this initiative focuses on providing specimens specifically tailored for analyzing immune mechanisms, with the strategic goal of increasing the success rate of developing next-generation immunotherapies. With the rapid growth of the immunotherapy market, the discovery of personalized biomarkers has become a key competitive advantage in drug development, making the establishment of this foundational infrastructure crucial.
Precise Data Acquisition Based on Standard Protocols
This project goes beyond simple sample storage, focusing on acquiring high-purity data through meticulously controlled protocols, including tissue biopsies and apheresis. The collected samples undergo immune cell isolation and advanced imaging diagnostics to analyze the physical and molecular interactions between cancer cells and immune cells. Standardizing the quality of research biospecimens in clinical settings is an essential prerequisite for obtaining reproducible research results. Considering that one of the biggest challenges faced by drug developers is securing reliable human tumor microenvironment data, the standardized protocols of this study can significantly reduce the risks associated with research and development.
Linkage with Next-Generation Immunotherapy Pipelines
The acquired samples are directly linked to various clinical protocols led by the NCI, serving as a foundation for basic research, including immune checkpoint inhibitors such as Avelumab and cancer immunotherapy vaccines such as PROSTVAC. Furthermore, they provide key data for analyzing the mechanisms of action of next-generation immune target drugs, including PD-1, PD-L1, CTLA-4, VISTA, and TGF-Ξ² and IL-15 superagonists. This goes beyond mere academic research, providing practical benefits by pre-validating the target suitability of new drugs and shortening the early clinical development period. In particular, it serves as strong evidence for designing combination therapies to overcome drug resistance, a major limitation in the treatment of solid tumors.
Long-Term Impact on the Immuno-Oncology Market
The global immunotherapy market is projected to grow rapidly from approximately $136.4 billion in 2025 to over $204.2 billion in 2030, with the North American market, centered in the United States, accounting for over 40% of this. Compared to private precision medicine platform companies such as Tempus AI and Guardant Health, the biobank led by the NCI, a national research institution, has the advantage of securing high reliability and standardization as a public database. This national-level infrastructure for standardizing tumor biospecimens is expected to play a pivotal role in accelerating the era of precision medicine. In the long term, it is expected to contribute to both improving healthcare cost-effectiveness and increasing patient survival rates by establishing an optimal drug prescription system based on individual patient immune profiles.
The NCI's NCT02682667 study aims to establish a national standard database that can improve drug development efficiency in the global immunotherapy market, which is expected to reach $136.4 billion in 2025. In the short term, it supports the rapid validation of efficacy for NCI clinical network drugs such as Avelumab and PROSTVAC, and in the medium to long term, it contributes to the development of companion diagnostic biomarkers for target validation and patient selection for new target immunotherapies such as VISTA, TGF-Ξ², and IL-15 superagonists. This provides tangible value to industry professionals by mitigating clinical design risks through public data in the tumor multi-omics data market, which is currently dominated by private companies such as Tempus AI and Guardant Health. Ultimately, it serves as a scientific validation tool for venture capital and institutional investors seeking to enhance the value of new drugs by reducing the failure rate of new drug candidates in early exploratory clinical trials (Phase 1/2).
Source: ClinicalTrials.gov (api_ct)